



Exelixis Announces June 19 Webcast of Presentation at the William Blair 28th Annual Growth Stock Conference

June 12, 2008

SOUTH SAN FRANCISCO, Calif., June 12 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that Frank Karbe, executive vice president and chief financial officer of Exelixis, will present at the William Blair & Company 28th Annual Growth Stock Conference at 1:10 p.m. PT/4:10 p.m. ET on Thursday, June 19, 2008. Mr. Karbe will discuss updates to the company's development pipeline and corporate strategy.

The presentation will be webcast and may be accessed in the Event Calendar page under Investors on the Exelixis website at <http://www.exelixis.com>.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company's website at <http://www.exelixis.com>.

SOURCE Exelixis, Inc.

CONTACT: Media, Soleil Maxwell Harrison, Senior Manager, Corporate Communications, +1-650-837-7012, sharrison@exelixis.com, or Investors, Charles Butler, Senior Director, Corporate Communications & Investor Relations, +1-650-837-7277, cbutler@exelixis.com, both of Exelixis, Inc.
Web site: <http://www.exelixis.com>